ZURICH, Switzerland, March 14 /PRNewswire/ -- Prionics announced the
acquisition of CEDI-Diagnostics. The Dutch firm is part of the world-famous
Wageningen University and Research Centre (Wageningen UR). Through the
purchase of CEDI, Prionics will acquire a substantial number of new products
and gain rights to commercialize developments made by the research centre.
Prionics and Wageningen UR have additionally agreed on a strategic
partnership for the development of future innovations in farm animal
With this acquisition, the successful Swiss company Prionics has
accomplished several objectives. "We have acquired a firm with tests proven
on the market and we gain access to future developments of a unique global
research centre", says Dr Markus Moser, co-CEO of Prionics.
"The Animal Science Group of Wageningen UR, a recognized leader in the
field of animal disease control, will contribute further potential for
innovation to Prionics", comments Dr. Bruno Oesch, co-CEO and Head of
Research & Development at Prionics AG.
The products made by CEDI include tests for the early diagnosis of foot
and mouth disease or swine fever. "The CEDI products are excellent tests
which make an ideal addition to our existing portfolio of farm animal
diagnostics", says Ernst Zollinger, Head of Marketing & Sales at Prionics AG.
Terms of the agreement include that Wageningen UR will acquire a stake in
Prionics. Further details are not disclosed.
CEDI-Diagnostics is a globally active company in the field of farm animal
diagnostics. The Dutch firm is a spin-off from the Animal Science Group of
Wageningen University. CEDI Diagnostics supplies more than twenty products
for the early detection of diseases in farm animals. The product portfolio
includes tests for the diagnosis of BSE, foot and mouth disease, BVDV (Bovine
Virus Diarrhoea Virus) and classical swine fever. With some 20 employees, the
business, founded in 2001, serves customers in over 60 countries.
About Wageningen UR
Wageningen UR is a collaboration between Wageningen University, the Van
Hall Larenstein School of Higher Professional Education and specialized
research institutes in areas such as food and food production, plant, animal,
environment and agricultural economics. With over 6000 employees and 9000
students, the business makes an active contribution to the resolution of
scientific, social and economic problems in the life science sector.
Wageningen UR works closely together with governments, institutions,
companies and the general public. Within Wageningen UR, Wageningen Business
Generator is responsible for the spin off companies and is positioned to
manage and commercialize corporate intellectual property.
The world leader in the diagnosis of BSE and other prion diseases
Prionics was founded in 1997 as a spin-off from Zurich University. At its
headquarters in Zurich, Prionics develops and markets diagnostic products for
the early diagnosis of farm animal diseases. The company places its main
focus on diseases which are transmissible from animals to human beings and
thereby contributing to an improvement to food safety. In October 2005
Prionics acquired Pfizer Animal Health's Diagnostic portfolio. The recipient
of the Swiss Economic Award 2002 as "Company of the year" and winner of the
European Biotech Award 2004 for Excellence in Biotech Business; Prionics is
driving its business through a combination of outstanding research,
high-quality products and innovative marketing solutions.
Director of Corporate Communications
Bouke de Vos
Press Officer Wageningen UR
SOURCE Prionics AG